Today: 22 November 2025
Subscribe
Browse Category

Earnings Reports News 30 October 2025

Baxter Stock Plummets 15% After Mixed Q3 Earnings – What Investors Should Know

Baxter Stock Plummets 15% After Mixed Q3 Earnings – What Investors Should Know

Mixed Third-Quarter Financial Results Baxter’s Q3 showed a mixed picture. Revenue from continuing operations rose about 5% year-over-year to $2.84 billion, helped by strong performance in its Pharmaceuticals and Healthcare Systems units baxter.com baxter.com. However, sales fell short of the street’s ~$2.88 billion estimate reuters.com. On profit, Baxter earned an adjusted $0.69 per share, well above the ~$0.60 expected reuters.com chartmill.com. (GAAP results showed a small net loss as some one-time costs were excluded from the adjusted figure baxter.com.) Despite the earnings beat, investors focused on the revenue miss. The stock tumbled ~15% in early trading on Oct. 30, 2025 reuters.com chartmill.com.
30 October 2025
 ·  ·  ·  ·  · 
Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Strong Q3 Earnings Propel Stock Higher Guardant’s latest quarterly report blew past Wall Street’s expectations, sparking a sharp rally in its shares. For Q3 2025, revenue was $265.2 million, a 39% jump from a year ago and well above the ~$235 million analysts had forecast investing.com. On an adjusted basis, Guardant lost $0.39 per share, much better than the roughly $0.79 loss expected. Management immediately lifted the full-year sales outlook to $965–970 million (about 31% growth) investors.guardanthealth.com, up from $915–925M previously. As a result, GH stock jumped nearly 30% in morning trading on Oct. 30 (to about $94, from ~$72
30 October 2025
 ·  ·  ·  ·  · 
Estée Lauder Stock Soars on Surprise Earnings Beat as Beauty Rebounds – What’s Next?

Estée Lauder Stock Soars on Surprise Earnings Beat as Beauty Rebounds – What’s Next?

Stock Performance and Reaction Estée Lauder’s stock seesawed on its earnings news. Shares initially surged in pre-market trading on Oct. 30 after the company’s strong quarterly report, jumping about 5% to roughly $102.26 ts2.tech. This early spike reflected investor surprise at the better-than-expected results. However, as the trading day wore on, some of those gains evaporated – by midday, EL stock hovered around $97.36, down ~1.4% from the prior close ts2.tech. (For context, Estée Lauder’s stock had already climbed sharply in recent months in anticipation of a recovery. It rallied about 60% over the past six months amid optimism about
30 October 2025
 ·  ·  ·  ·  · 
Medical Properties Trust Defies Skeptics: Q3 Beat and Buyback Ignite 6%‑Yield REIT Rally

Medical Properties Trust Defies Skeptics: Q3 Beat and Buyback Ignite 6%‑Yield REIT Rally

Q3 Earnings Surprise and Portfolio Updates Medical Properties Trust’s third-quarter results provided a dose of relief for investors who have endured a turbulent year. Normalized FFO came in at $0.13 per share, comfortably ahead of what many analysts had expected (consensus was near $0.08, with some forecasts as low as essentially breakeven) chartmill.com. This key profit metric for REITs was down from $0.16 a year ago businesswire.com, reflecting ongoing challenges, but the “beat” versus expectations drew focus. “Investors responded positively to the earnings beat and management’s optimistic commentary,” noted ChartMill, after MPW shares rose about 2–3% in pre-market trading on
30 October 2025
 ·  ·  ·  ·  · 
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

BMY Stock Bounces After Earnings – Recent Performance Bristol Myers Squibb’s stock has been under pressure for most of 2025, but the Q3 report provided a much-needed boost. Heading into earnings, BMY shares were near 52-week lows, reflecting investor skittishness over looming patent cliffs and mixed news in prior quarters. In fact, on October 28, the stock touched a one-year low of $42.96 (closing at $42.99) marketbeat.com. That put BMY down roughly 18–19% year-to-date, significantly underperforming the pharma sector (which was roughly flat to slightly up over the same period) nasdaq.com. By comparison, an index of large pharmaceutical stocks was
30 October 2025
 ·  ·  ·  · 
Altria Stock Slips After Mixed Q3 Earnings – Big Buyback and 8% Dividend Tempt Investors

Altria Stock Slips After Mixed Q3 Earnings – Big Buyback and 8% Dividend Tempt Investors

MO Stock Slides on Mixed Earnings Altria’s third-quarter earnings highlight the tobacco giant’s balancing act between resilient profits and declining cigarette usage. The company reported an adjusted Q3 profit of $1.45 per share, a 3.6% increase year-on-year and exactly in line with analyst expectations reuters.com. However, revenue fell more than anticipated – net revenues came in at $6.07 billion, down ~3% from a year ago reuters.com. This topline drop exceeded Wall Street’s forecasts and underscored weaker cigarette volumes. The mixed results put immediate pressure on MO stock, which fell about 4% ahead of Thursday’s open on the news reuters.com. Even after
30 October 2025
 ·  ·  ·  ·  · 
Comcast Shocker: Cord-Cutting Slows, Wireless Soars in Q3 Earnings

Comcast Shocker: Cord-Cutting Slows, Wireless Soars in Q3 Earnings

Earnings Beat Expectations (Despite Olympic Comparisons) Comcast’s Q3 results trounced Street forecasts. Net income of $3.33 billion (¥8.2% YoY) translated to $0.90 GAAP EPS, or $1.12 adjusted EPS (vs. ≈$1.10 consensus) on $31.2 billion revenue thewrap.com. The revenue marked a 2.7% YoY decline, but topped analyst models (~$30.7B). Crucially, last year’s quarter was inflated by the Paris Olympics (adding ~$1.9B in revenue), so year-on-year comparisons were unfavorable thewrap.com. Even with that Olympic tailwind, Comcast beat estimates, suggesting resilience in its core businesses. Contributing to the beat, Comcast’s theme parks and content divisions thrived. Universal’s new Epic Universe park drove theme-park revenue up
30 October 2025
 ·  ·  ·  ·  · 
Mastercard Stock Rockets on Q3 Earnings Beat and $2B Crypto Play – What Investors Should Know

Mastercard Stock Rockets on Q3 Earnings Beat and $2B Crypto Play – What Investors Should Know

Strong Q3 Earnings and Spending Trends Mastercard’s Oct. 30 earnings report beat expectations, lifting the stock. The payments giant logged Q3 revenue of $8.60 billion, up 17% from a year earlier investing.com, and adjusted EPS of $4.38 (above the $4.32 Wall Street estimate) investing.com. Revenue from cross-border spending jumped ~15%, and its higher-margin services (fraud protection, data analytics, etc.) grew ~25% YoY investing.com. Net profit rose to $3.96 billion reuters.com, reflecting resilient consumer and business spending despite inflation and trade concerns. CEO Michael Miebach told analysts the quarter showed “healthy consumer and business spending” investing.com. Indeed, Mastercard said everyday purchases and travel remained
30 October 2025
 ·  ·  ·  · 
Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Inc. (Nasdaq: BIIB) is a leading neuroscience biotech known for multiple sclerosis and rare-disease therapies ts2.tech. On Oct. 30, 2025 the stock dipped after a mixed earnings release. The company beat Q3 expectations – adjusted EPS $4.81 vs. $3.88 est and $2.53 B revenue vs. $2.34 B est ng.investing.com – but lowered its full-year outlook. Biogen now expects 2025 non-GAAP EPS of $14.50–$15.00 (previously $15.50–16.00), citing an anticipated ~$1.25 per-share charge in Q4 for recent R&D deals reuters.com reuters.com. CEO Chris Viehbacher spun the quarter positively, noting “we delivered another quarter of strong financial performance driven by … momentum in our
30 October 2025
 ·  ·  ·  · 
Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

CI Stock Price and Recent Trend Cigna’s stock has pulled back modestly in late October after a strong run earlier in the year. According to market data, CI closed at $299.12 on Oct 29, 2025, down about 3% from the previous close stockanalysis.com. The dip followed weakness in broader managed-care stocks amid concerns about healthcare costs and policy. In pre-market trading Oct 30, CI rebounded to about $303 (up ~1.3%) reuters.com. Over the past year, CI shares have traded between roughly $257 and $350 stockanalysis.com, reflecting volatility in the insurance sector. Despite the pullback, Cigna’s valuation metrics remain attractive: at
30 October 2025
 ·  ·  ·  · 
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Dips on Earnings Beat — Will Pipeline Boost Spur a Rally?

Merck’s stock price dipped on Oct 30, 2025 even as it delivered a strong third-quarter report. The company posted $17.28 B in Q3 sales and $2.58 adjusted EPS – above analyst forecasts marketscreener.com. Sales of Keytruda, its blockbuster cancer drug, grew about 10% (to $8.1 B) marketscreener.com, offsetting a drop in Gardasil vaccine revenue. Despite the beat, Merck narrowed its 2025 sales outlook (now $64.5–65.0 B) while slightly raising profit guidance marketscreener.com, a cautious stance that likely weighed on the share price. Pipeline and Drug Approvals Drive Hopes Beyond the quarterly numbers, recent product news is energizing Merck’s outlook. In September 2025 the
30 October 2025
 ·  ·  ·  ·  · 
1 … 31 32 33 34 35 … 48
Go toTop